NCT03924609 is a clinical trial of Intensive screening / routine screening in Breast Cancer, sponsored by Peking University People's Hospital.

Who is sponsoring NCT03924609?

NCT03924609 is sponsored by Peking University People's Hospital.

What drugs are being tested in NCT03924609?

Interventions in NCT03924609: Intensive screening / routine screening.

What condition does NCT03924609 study?

NCT03924609 studies Breast Cancer, Bone Metastases.

Is NCT03924609 still recruiting?

NCT03924609 is currently completed. Last updated 23 April 2019.

Last reviewed 2019-04-23 · How we verify

NCT03924609

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Intensive Follow-up for Bone Metastasis on Characteristics and Prognosis of Chinese Breast Cancer Patients

Completed Last updated 23 April 2019

What this trial tests

trial testing Intensive screening / routine screening in Breast Cancer in 1,500 participants. Completed in 31 March 2019.

Timeline

1 March 2018

Primary endpoint
31 March 2019

31 March 2019

Quick facts

Lead sponsor	Peking University People's Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,500
Start date	1 March 2018
Primary completion	31 March 2019
Estimated completion	31 March 2019
Sites	1 location across China

Drugs / interventions tested

Intensive screening / routine screening

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Bone Metastases — all drugs for Bone Metastases →

Sponsor

Peking University People's Hospital

Who can join

Adults 18 to 70, female only, with Breast Cancer or Bone Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to retrospectively collect and analyse the characteristics of breast cancer patients with bone metastasis, and compare the impact of intensive follow-up with standard post-operative surveillance on survival of Chinese breast cancer patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Survival in Breast Cancer Patients with Bone Metastasis: A Multicenter Real-World Study on the Prognostic Impact of Intensive Postoperative Bone Scan after Initial Diagnosis of Breast Cancer (CSBrS-023).
Yang L, Du W, Hu T, Liu M, et al · · 2022 · cited 3× · PMID 36497317 · DOI 10.3390/cancers14235835

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03924609 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 23 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03924609.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing